CN110184275A - 一种nf1新突变致病基因及应用和试剂盒 - Google Patents

一种nf1新突变致病基因及应用和试剂盒 Download PDF

Info

Publication number
CN110184275A
CN110184275A CN201910530764.4A CN201910530764A CN110184275A CN 110184275 A CN110184275 A CN 110184275A CN 201910530764 A CN201910530764 A CN 201910530764A CN 110184275 A CN110184275 A CN 110184275A
Authority
CN
China
Prior art keywords
leu
ser
ala
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910530764.4A
Other languages
English (en)
Other versions
CN110184275B (zh
Inventor
余涛
孟晓红
刘沙
齐冬梅
任佳云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of PLA Military Medical University
Original Assignee
First Affiliated Hospital of PLA Military Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of PLA Military Medical University filed Critical First Affiliated Hospital of PLA Military Medical University
Priority to CN201910530764.4A priority Critical patent/CN110184275B/zh
Publication of CN110184275A publication Critical patent/CN110184275A/zh
Application granted granted Critical
Publication of CN110184275B publication Critical patent/CN110184275B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明涉及一种和神经纤维瘤病1型疾病相关的NF1新突变致病基因,属于分子生物学领域,所述新突变致病基因的核酸样本与NF1基因如SEQ ID NO:1所示的核苷酸序列相比,核苷酸变化:c.738delA;还涉及到由新突变致病基因编码的突变体蛋白。本发明首次揭示了NF1基因c.738delA位点突变与神经纤维瘤病1型疾病相关,提供了新突变致病基因在制备检测或筛选NF1病变的试剂或试剂盒中的应用。进一步提供筛选神经纤维瘤病1型疾病的试剂盒,完善更多的神经纤维瘤病1型疾病突变基因,为患者及时发现及时治疗提供更可靠的指导。

Description

一种NF1新突变致病基因及应用和试剂盒
技术领域
本发明属于生物技术中突变基因领域,涉及一种NF1新突变致病基因及应用和试剂盒。
背景技术
神经纤维瘤病1型(NF1)是一种以遗传性疾病为特征的遗传性疾病,患有NF1的个体患各种肿瘤的风险增加。NF1基因是1型神经纤维瘤(neurofibromatosis type 1,NF1)患者生殖系中突变的抑癌基因,最常见的肿瘤包括神经纤维瘤、丛状神经纤维瘤、周围神经鞘恶性肿瘤和视神经胶质瘤;NF1的体细胞突变在癌症中很常见,包括黑色素瘤。
NF1的特征是皮肤和眼睛的色素病变,包括多个皮肤神经纤维瘤、咖啡-au-lait斑、腋窝腹股沟雀斑、脉络膜雀斑和虹膜Lisch结节。Lisch结节是眼睛的黑素细胞错构瘤,在虹膜上表现为界限清楚的圆顶状丘疹,透明至黄色或棕色,其组织学上表现为黑素细胞聚集,并与梭形细胞和肥大细胞混合。目前尚未明确Lisch结节导致的眼部并发症。不太常见但可能更严重的表现包括青光眼、视神经和其他中枢神经系统胶质瘤,恶性外周神经鞘瘤,脊柱侧凸,胫骨发育不良和血管病变。
儿童每年的眼科检查是对于该疾病的监控手段之一,由熟悉该疾病的医生每年进行体检,对儿童进行定期发展评估。NF1患者的视神经胶质瘤通常在6岁之前出现视力下降,突眼或斜视[Friedrich&Nuding 2016]。Lisch结节几乎可以在所有成人和不到一半小于5岁的NF1儿童中中看到。[Ragge等1993]。在标准眼科检查中无法看到脉络膜雀斑,但可以通过红外或近红外光扫描激光检眼镜,红外反射成像或光学相干断层扫描来观察脉络膜雀斑[Vagge等2016],其病理改变是雪旺细胞增殖排列在轴突周围的同心环中,发生在大多数所有年龄的NF1患者中,并随着年龄的增长而增多。NF1的罕见眼部表现包括视网膜血管增生性肿瘤[Hood等人2009,Shields等人2014]和新生血管性青光眼[Elgi等人2010,Chiu等人2011,Al Freihi等人2013]。
NF1的诊断通常基于临床发现,但这种疾病的表现是非常多变的,即使在一个家庭中也可以出现多种临床表现。所以需要结合NF1的分子遗传学检测来明确诊断。NF1遗传方式为常染色体显性遗传。半数受影响的个体由于一种新的NF1致病变异而具有NF1。受影响个体的后代有50%的风险遗传变异的NF1等位基因。
NF1基因位于染色体17q11.2,全长为282 751bp,包含58个外显子,编码2839个氨基酸,编码神经纤维瘤蛋白,负责调控Ras蛋白转导信号。已经鉴定出数千种不同的NF1致病变异,包括错义/无义、剪接、小片段的插入/缺失、大片段的插入/缺失等各种突变类型,分布在整个编码区,大多数致病性变异是特定家族特有的。所以科研人员不遗余力的鉴定出每一个NF1致病变异的基因,以应用生物技术检测手段检查出NF1病变的可能性,及时的进行治疗干预,尽可能的减少患者视力衰退是当前科研人员迫不及待的心愿。
发明内容
有鉴于此,本发明的目的在于提供一种NF1新突变致病基因,以便更加完善NF1致病变异基因,在临床发现前期能通过生物基因筛查手段更及时的发现NF1病变的可能性,及时的进行治疗干预,让患者早日康复。
为达到上述目的,本发明提供如下技术方案:
1、一种NF1新突变致病基因,所述新突变致病基因的核酸样本与NF1基因如SEQ IDNO:1所示的核苷酸序列相比,核苷酸变化:c.738delA。
进一步,所述突变致病基因的核酸样本指人工分离或合成的单链DNA、双链DNA、RNA或DNA与RNA的聚合物。
2、本发明还提供一种视网膜变性疾病的NF1新突变体多肽,所述多肽的氨基酸序列与SEQ ID NO:2所示的氨基酸序列相比,氨基酸变化:p.E247KfsTer34。
进一步,所述多肽由权利要求1所述的基因编码的。
3、本发明还提供一种NF1新突变致病基因在制备检测或筛选NF1病变的试剂盒中的应用。所述新突变致病基因的核酸样本与NF1基因如SEQ ID NO:1所示的核苷酸序列相比,核苷酸变化:c.738delA。
4、本发明还提供一种筛选NF1病变的试剂盒,所述试剂盒包含检测NF1新突变致病基因的试剂,所述新突变致病基因与NF1基因如SEQ ID NO:1所示的核苷酸序列相比,具有核苷酸变化:c.738delA。
进一步,所述试剂盒检测的核酸样本指人工分离或合成的单链DNA、双链DNA、RNA或DNA与RNA的聚合物。
进一步,所述检测NF1新突变致病基因的试剂是核酸探针。
进一步,所述试剂盒还包括序列如SEQ ID NO:15和/或SEQ ID NO:16的引物。
进一步,所述试剂盒还包括序列如SEQ ID NO:3-SEQ ID NO:94的一个或多个引物。
进一步,所述检测NF1新突变致病基因的试剂是检测致病基因所编码的蛋白。
进一步,所述蛋白的氨基酸与SEQ ID NO:2所示的氨基酸序列相比,具有p.E247KfsTer34突变。
本发明的有益效果在于:本发明首次提供了NF1基因一个新的突变位点,与NF1野生型基因相比,核苷酸c.738delA位点突变,且与NF1疾病密切相关,并以此设计出直接检测该突变基因的试剂盒。本发明所提供了NF1基因一个新的突变位点更加完善NF1致病变异基因,为在临床发现前期能通过生物基因筛查手段更及时的发现NF1病变提供更多更有力的检测工具,能及时的进行治疗干预,让患者早日康复创造福音。本发明所提供了NF1基因一个新的突变位点,可以单独的开发直接检测该突变基因的试剂盒,也可以联合检测其他已知突变基因开发试剂盒。
本发明所述的试剂盒可以直接通过一代测序,减少繁琐程序,跳过高通量筛选,直接针对目的基因外显子全长测序,也可以直接针对28号外显子测序。本发明所提供的引物设计,PCR扩增加上一代测序对基因外显子突变进行检测,操作简单,技术成熟,成本极低,不受突变大小(20bp)影响,可对外显子纯合缺失及大片断缺失插入进行检测。
附图说明
为了使本发明的目的、技术方案和有益效果更加清楚,本发明提供如下附图进行说明:
图1为患者面部、胸部和腹部的牛奶咖啡斑,其中上图为患者胸部牛奶咖啡斑图,下图为患者腹部牛奶咖啡斑图。
图2为患者眼科检查结果,其中a和b分别为患者左眼和右眼眼底彩照,c和d分别为患者左眼和右眼NIR双眼近红外光眼底扫描。
图3为该患者右眼九方位眼底彩照和眼底血管荧光造影检查图。
图4为该患者父亲眼科检查结果,其中a和b分别为患者父亲左眼和右眼眼底彩照,眼底彩照显示双眼眼底未见明显异常;图4中c和d分别为患者父亲左眼和右眼NIR,NIR显示双眼后极部和中周部视网膜多灶团状和斑块状强反射。
图5为患者父亲背部照片。
图6为患者外显子8一代测序部分结果。
图7为该患者父亲在外显子8位点的验证。
图8为该患者母亲在外显子8位点的验证。
图9为该患者家系图,其中M为突变体,N为野生型。
具体实施方式
下面将结合附图,对本发明的优选实施例进行详细的描述。实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。
实施例1
获取生物样品
2018年,门诊收取一患者,临床表型为:新生血管性青光眼,视网膜血管增生性肿瘤,皮肤有牛奶咖啡斑,临床怀疑神经纤维瘤病1型。父亲及外婆皮肤有牛奶咖啡斑,视力正常,母亲和妹妹表型正常,样本为疾病患者及其父母的外周静脉血。所有参与本发明研究的家系成员均签署了知情同意书。(男孩,年龄7岁,(2011年),父亲,年龄32岁,(1986年);母亲:年龄29岁(1990年);妹妹:年龄,4岁(2015);外婆:57岁,(1962年)。
该患者面部、胸部和腹部均有大小不等的牛奶咖啡斑,如图1所示,其中上图为患者胸部牛奶咖啡斑图,下图为患者腹部牛奶咖啡斑图。
图2为该患者眼科检查结果,其中a和b分别为患者左眼和右眼眼底彩照,患者眼底彩照显示左眼眼底未见明显异常,患儿右眼因玻璃体浑浊眼底图像显示不清。图2中c和d分别为患者左眼和右眼NIR双眼近红外光眼底扫描(Near-infrared Reflectance,NIR),显示左眼后极部和中周部视网膜多灶团状和斑块状强反射,右眼显示不清。图3为该患者右眼九方位眼底彩照和眼底血管荧光造影检查图,如图3左边图所示,右眼颞上方周边视网膜见灰白色斑块状结节样改变,融合成片,边界不清,其间隐约见形态异常血管。如图3右边图所示,FFA(眼底血管荧光造影)显示右眼颞上方周边部分视网膜血管轻微扩张,后期部分管壁荧光染色。
图4为该患者父亲眼科检查结果,其中a和b分别为患者父亲左眼和右眼眼底彩照,眼底彩照显示双眼眼底未见明显异常;图4中c和d分别为患者父亲左眼和右眼NIR,NIR显示双眼后极部和中周部视网膜多灶团状和斑块状强反射。
该患者父亲全身皮肤散在斑块状及椒盐状色素沉着改变(咖啡斑),面部、颈部和背部均有,涉及患者隐私,只显示该患者父亲背部照片,如图5所示。
实施例2DNA提取
利用高盐沉淀法提取各血液样本中基因组DNA,利用分光光度计测量DNA的浓度及纯度,所得的每个标本基因组DNA的OD260/OD280均位于1.7-2.0之间,浓度不少于200ng/微升,总量不少于30微克。
实施例3引物设计及PCR反应
参考人类基因组序列数据库,设计得NF1基因1-58号外显子序列分别对应的PCR特异性引物对,具体内容如表1所示,1-58号外显子所对应的序列如表2所示。
表1 NF1基因1-58号外显子序列分别对应的PCR特异性引物对
表2 1-58号外显子所对应的基因
接着,分别按照以下配比配制各基因组DNA样本的PCR反应体系以及进行PCR反应,其中PCR使用的Promga品牌的Go Green Master Mix,lot号000242981。
按照表1针对NF1基因1-58号外显子序列,按表3配比分别配制各基因组DNA样本的各PCR反应体系,PCR反应体系为40ul。
按照表1针对NF1基因1-58号外显子序列,按表3配比分别配制各基因组DNA样本的各PCR反应体系,PCR反应体系为40ul。
表3:PCR反应体系(40ul)
再将以上配置好的各反应体系按照表4的反应条件进行PCR反应。
表4:PCR程序
实施例4Sanger法测序验证
将所获得的PCR扩增产物直接进行Sanger法测序验证。
PCR产物纯化:实施例3中得到的PCR产物经1%的琼脂糖凝胶电泳,160V,40-60Min。紫外透射仪下割下目的条带。切取的胶块质量应小于3g,于96孔板中按照胶块质量:Buffer GL=1:3加入Buffer GL,盖上封口膜,65℃水浴12min,揭开封口膜,用连续加液器每孔加入100μl已经混匀的磁珠,磁珠吸附目的DNA。在磁力的作用下固定磁珠,Eluent或无菌水洗脱磁珠表面上目的DNA。
目的条带于96孔PCR板中进行测序PCR扩增:
测序反应PCR:采用正向或反向引物扩增
表4:测序PCR反应体系(5ul)
BDT(BDT原液:5x Buffer=1:3) 1ul
正向/反向引物(10P) 1ul
DNA模板(200ng/μl) 2ul
ddH<sub>2</sub>O 1ul(add up to 5ul)
表5:PCR程序
测序扩增后的产物移至ABI3730测序仪,测序分析。使用CodonCode Aligner软件读取测序峰图,并将测序结果与参考序列比对。
结果如下:患者及患者父亲发现了核苷酸变异:738delA,导致后面的序列移码,对应氨基酸变化:p.E247KfsTer34。患者母亲核苷酸没有突变,为野生型。
图6为患者外显子8一代测序部分结果,其中在序列510位(核苷酸738位)碱基A丢失,由正常序列GCAGA变为GC_GA。
图7为该患者父亲在外显子8位点的验证;父亲验证在510位(核苷酸738位)碱基A丢失,由正常序列GCAGA变为GC_GA。
图8为该患者母亲在外显子8位点的验证;母亲验证在510位(核苷酸738位)为野生型。
图9为该患者家系图,其中M为突变体,N为野生型。
此方法可直接通过一代测序,直接针对目的基因外显子全长测序,能清楚知道外显子的情况,继而清楚NF1基因的突变情况可能导致的病变,简单直接有效。
最后说明的是,以上优选实施例仅用以说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
序列表
<110> 中国人民解放军陆军军医大学第一附属医院
<120> 一种NF1新突变致病基因及应用和试剂盒
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 12381
<212> DNA
<213> Homo sapiens
<400> 1
aatctctagc tcgctcgcgc tccctctccc cgggccgtgg aaaggatccc acttccggtg 60
gggtgtcatg gcggcgtctc ggactgtgat ggctgtgggg agacggcgct agtggggaga 120
gcgaccaaga ggccccctcc cctccccggg tccccttccc ctatccccct ccccccagcc 180
tccttgccaa cgcccccttt ccctctcccc ctcccgctcg gcgctgaccc cccatcccca 240
cccccgtggg aacactggga gcctgcactc cacagaccct ctccttgcct cttccctcac 300
ctcagcctcc gctccccgcc ctcttcccgg cccagggcgc cggcccaccc ttccctccgc 360
cgccccccgg ccgcggggag gacatggccg cgcacaggcc ggtggaatgg gtccaggccg 420
tggtcagccg cttcgacgag cagcttccaa taaaaacagg acagcagaac acacatacca 480
aagtcagtac tgagcacaac aaggaatgtc taatcaatat ttccaaatac aagttttctt 540
tggttataag cggcctcact actattttaa agaatgttaa caatatgaga atatttggag 600
aagctgctga aaaaaattta tatctctctc agttgattat attggataca ctggaaaaat 660
gtcttgctgg gcaaccaaag gacacaatga gattagatga aacgatgctg gtcaaacagt 720
tgctgccaga aatctgccat tttcttcaca cctgtcgtga aggaaaccag catgcagctg 780
aacttcggaa ttctgcctct ggggttttat tttctctcag ctgcaacaac ttcaatgcag 840
tctttagtcg catttctacc aggttacagg aattaactgt ttgttcagaa gacaatgttg 900
atgttcatga tatagaattg ttacagtata tcaatgtgga ttgtgcaaaa ttaaaacgac 960
tcctgaagga aacagcattt aaatttaaag ccctaaagaa ggttgcgcag ttagcagtta 1020
taaatagcct ggaaaaggca ttttggaact gggtagaaaa ttatccagat gaatttacaa 1080
aactgtacca gatcccacag actgatatgg ctgaatgtgc agaaaagcta tttgacttgg 1140
tggatggttt tgctgaaagc accaaacgta aagcagcagt ttggccacta caaatcattc 1200
tccttatctt gtgtccagaa ataatccagg atatatccaa agacgtggtt gatgaaaaca 1260
acatgaataa gaagttattt ctggacagtc tacgaaaagc tcttgctggc catggaggaa 1320
gtaggcagct gacagaaagt gctgcaattg cctgtgtcaa actgtgtaaa gcaagtactt 1380
acatcaattg ggaagataac tctgtcattt tcctacttgt tcagtccatg gtggttgatc 1440
ttaagaacct gctttttaat ccaagtaagc cattctcaag aggcagtcag cctgcagatg 1500
tggatctaat gattgactgc cttgtttctt gctttcgtat aagccctcac aacaaccaac 1560
actttaagat ctgcctggct cagaattcac cttctacatt tcactatgtg ctggtaaatt 1620
cactccatcg aatcatcacc aattccgcat tggattggtg gcctaagatt gatgctgtgt 1680
attgtcactc ggttgaactt cgaaatatgt ttggtgaaac acttcataaa gcagtgcaag 1740
gttgtggagc acacccagca atacgaatgg caccgagtct tacatttaaa gaaaaagtaa 1800
caagccttaa atttaaagaa aaacctacag acctggagac aagaagctat aagtatcttc 1860
tcttgtccat ggtgaaacta attcatgcag atccaaagct cttgctttgt aatccaagaa 1920
aacaggggcc cgaaacccaa ggcagtacag cagaattaat tacagggctc gtccaactgg 1980
tccctcagtc acacatgcca gagattgctc aggaagcaat ggaggctctg ctggttcttc 2040
atcagttaga tagcattgat ttgtggaatc ctgatgctcc tgtagaaaca ttttgggaga 2100
ttagctcaca aatgcttttt tacatctgca agaaattaac tagtcatcaa atgcttagta 2160
gcacagaaat tctcaagtgg ttgcgggaaa tattgatctg caggaataaa tttcttctta 2220
aaaataagca ggcagataga agttcctgtc actttctcct tttttacggg gtaggatgtg 2280
atattccttc tagtggaaat accagtcaaa tgtccatgga tcatgaagaa ttactacgta 2340
ctcctggagc ctctctccgg aagggaaaag ggaactcctc tatggatagt gcagcaggat 2400
gcagcggaac ccccccgatt tgccgacaag cccagaccaa actagaagtg gccctgtaca 2460
tgtttctgtg gaaccctgac actgaagctg ttctggttgc catgtcctgt ttccgccacc 2520
tctgtgagga agcagatatc cggtgtgggg tggatgaagt gtcagtgcat aacctcttgc 2580
ccaactataa cacattcatg gagtttgcct ctgtcagcaa tatgatgtca acaggaagag 2640
cagcacttca gaaaagagtg atggcactgc tgaggcgcat tgagcatccc actgcaggaa 2700
acactgaggc ttgggaagat acacatgcaa aatgggaaca agcaacaaag ctaatcctta 2760
actatccaaa agccaaaatg gaagatggcc aggctgctga aagccttcac aagaccattg 2820
ttaagaggcg aatgtcccat gtgagtggag gaggatccat agatttgtct gacacagact 2880
ccctacagga atggatcaac atgactggct tcctttgtgc ccttggggga gtgtgcctcc 2940
agcagagaag caattctggc ctggcaacct atagcccacc catgggtcca gtcagtgaac 3000
gtaagggttc tatgatttca gtgatgtctt cagagggaaa cgcagataca cctgtcagca 3060
aatttatgga tcggctgttg tccttaatgg tgtgtaacca tgagaaagtg ggacttcaaa 3120
tacggaccaa tgttaaggat ctggtgggtc tagaattgag tcctgctctg tatccaatgc 3180
tatttaacaa attgaagaat accatcagca agttttttga ctcccaagga caggttttat 3240
tgactgatac caatactcaa tttgtagaac aaaccatagc tataatgaag aacttgctag 3300
ataatcatac tgaaggcagc tctgaacatc tagggcaagc tagcattgaa acaatgatgt 3360
taaatctggt caggtatgtt cgtgtgcttg ggaatatggt ccatgcaatt caaataaaaa 3420
cgaaactgtg tcaattagtt gaagtaatga tggcaaggag agatgacctc tcattttgcc 3480
aagagatgaa atttaggaat aagatggtag aatacctgac agactgggtt atgggaacat 3540
caaaccaagc agcagatgat gatgtaaaat gtcttacaag agatttggac caggcaagca 3600
tggaagcagt agtttcactt ctagctggtc tccctctgca gcctgaagaa ggagatggtg 3660
tggaattgat ggaagccaaa tcacagttat ttcttaaata cttcacatta tttatgaacc 3720
ttttgaatga ctgcagtgaa gttgaagatg aaagtgcgca aacaggtggc aggaaacgtg 3780
gcatgtctcg gaggctggca tcactgaggc actgtacggt ccttgcaatg tcaaacttac 3840
tcaatgccaa cgtagacagt ggtctcatgc actccatagg cttaggttac cacaaggatc 3900
tccagacaag agctacattt atggaagttc tgacaaaaat ccttcaacaa ggcacagaat 3960
ttgacacact tgcagaaaca gtattggctg atcggtttga gagattggtg gaactggtca 4020
caatgatggg tgatcaagga gaactcccta tagcgatggc tctggccaat gtggttcctt 4080
gttctcagtg ggatgaacta gctcgagttc tggttactct gtttgattct cggcatttac 4140
tctaccaact gctctggaac atgttttcta aagaagtaga attggcagac tccatgcaga 4200
ctctcttccg aggcaacagc ttggccagta aaataatgac attctgtttc aaggtatatg 4260
gtgctaccta tctacaaaaa ctcctggatc ctttattacg aattgtgatc acatcctctg 4320
attggcaaca tgttagcttt gaagtggatc ctaccaggtt agaaccatca gagagccttg 4380
aggaaaacca gcggaacctc cttcagatga ctgaaaagtt cttccatgcc atcatcagtt 4440
cctcctcaga attcccccct caacttcgaa gtgtgtgcca ctgtttatac caggtggtta 4500
gccagcgttt ccctcagaac agcatcggtg cagtaggaag tgccatgttc ctcagattta 4560
tcaatcctgc cattgtctca ccgtatgaag cagggatttt agataaaaag ccaccaccta 4620
gaatcgaaag gggcttgaag ttaatgtcaa agatacttca gagtattgcc aatcatgttc 4680
tcttcacaaa agaagaacat atgcggcctt tcaatgattt tgtgaaaagc aactttgatg 4740
cagcacgcag gtttttcctt gatatagcat ctgattgtcc tacaagtgat gcagtaaatc 4800
atagtctttc cttcataagt gacggcaatg tgcttgcttt acatcgtcta ctctggaaca 4860
atcaggagaa aattgggcag tatctttcca gcaacaggga tcataaagct gttggaagac 4920
gaccttttga taagatggca acacttcttg catacctggg tcctccagag cacaaacctg 4980
tggcagatac acactggtcc agccttaacc ttaccagttc aaagtttgag gaatttatga 5040
ctaggcatca ggtacatgaa aaagaagaat tcaaggcttt gaaaacgtta agtattttct 5100
accaagctgg gacttccaaa gctgggaatc ctatttttta ttatgttgca cggaggttca 5160
aaactggtca aatcaatggt gatttgctga tataccatgt cttactgact ttaaagccat 5220
attatgcaaa gccatatgaa attgtagtgg accttaccca taccgggcct agcaatcgct 5280
ttaaaacaga ctttctctct aagtggtttg ttgtttttcc tggctttgct tacgacaacg 5340
tctccgcagt ctatatctat aactgtaact cctgggtcag ggagtacacc aagtatcatg 5400
agcggctgct gactggcctc aaaggtagca aaaggcttgt tttcatagac tgtcctggga 5460
aactggctga gcacatagag catgaacaac agaaactacc tgctgccacc ttggctttag 5520
aagaggacct gaaggtattc cacaatgctc tcaagctagc tcacaaagac accaaagttt 5580
ctattaaagt tggttctact gctgtccaag taacttcagc agagcgaaca aaagtcctag 5640
ggcaatcagt ctttctaaat gacatttatt atgcttcgga aattgaagaa atctgcctag 5700
tagatgagaa ccagttcacc ttaaccattg caaaccaggg cacgccgctc accttcatgc 5760
accaggagtg tgaagccatt gtccagtcta tcattcatat ccggacccgc tgggaactgt 5820
cacagcccga ctctatcccc caacacacca agattcggcc aaaagatgtc cctgggacac 5880
tgctcaatat cgcattactt aatttaggca gttctgaccc gagtttacgg tcagctgcct 5940
ataatcttct gtgtgcctta acttgtacct ttaatttaaa aatcgagggc cagttactag 6000
agacatcagg tttatgtatc cctgccaaca acaccctctt tattgtctct attagtaaga 6060
cactggcagc caatgagcca cacctcacgt tagaattttt ggaagagtgt atttctggat 6120
ttagcaaatc tagtattgaa ttgaaacacc tttgtttgga atacatgact ccatggctgt 6180
caaatctagt tcgtttttgc aagcataatg atgatgccaa acgacaaaga gttactgcta 6240
ttcttgacaa gctgataaca atgaccatca atgaaaaaca gatgtaccca tctattcaag 6300
caaaaatatg gggaagcctt gggcagatta cagatctgct tgatgttgta ctagacagtt 6360
tcatcaaaac cagtgcaaca ggtggcttgg gatcaataaa agctgaggtg atggcagata 6420
ctgctgtagc tttggcttct ggaaatgtga aattggtttc aagcaaggtt attggaagga 6480
tgtgcaaaat aattgacaag acatgcttat ctccaactcc tactttagaa caacatctta 6540
tgtgggatga tattgctatt ttagcacgct acatgctgat gctgtccttc aacaattccc 6600
ttgatgtggc agctcatctt ccctacctct tccacgttgt tactttctta gtagccacag 6660
gtccgctctc ccttagagct tccacacatg gactggtcat taatatcatt cactctctgt 6720
gtacttgttc acagcttcat tttagtgaag agaccaagca agttttgaga ctcagtctga 6780
cagagttctc attacccaaa ttttacttgc tgtttggcat tagcaaagtc aagtcagctg 6840
ctgtcattgc cttccgttcc agttaccggg acaggtcatt ctctcctggc tcctatgaga 6900
gagagacttt tgctttgaca tccttggaaa cagtcacaga agctttgttg gagatcatgg 6960
aggcatgcat gagagatatt ccaacgtgca agtggctgga ccagtggaca gaactagctc 7020
aaagatttgc attccaatat aatccatccc tgcaaccaag agctcttgtt gtctttgggt 7080
gtattagcaa acgagtgtct catgggcaga taaagcagat aatccgtatt cttagcaagg 7140
cacttgagag ttgcttaaaa ggacctgaca cttacaacag tcaagttctg atagaagcta 7200
cagtaatagc actaaccaaa ttacagccac ttcttaataa ggactcgcct ctgcacaaag 7260
ccctcttttg ggtagctgtg gctgtgctgc agcttgatga ggtcaacttg tattcagcag 7320
gtaccgcact tcttgaacaa aacctgcata ctttagatag tctccgtata ttcaatgaca 7380
agagtccaga ggaagtattt atggcaatcc ggaatcctct ggagtggcac tgcaagcaaa 7440
tggatcattt tgttggactc aatttcaact ctaactttaa ctttgcattg gttggacacc 7500
ttttaaaagg gtacaggcat ccttcacctg ctattgttgc aagaacagtc agaattttac 7560
atacactact aactctggtt aacaaacaca gaaattgtga caaatttgaa gtgaatacac 7620
agagcgtggc ctacttagca gctttactta cagtgtctga agaagttcga agtcgctgca 7680
gcctaaaaca tagaaagtca cttcttctta ctgatatttc aatggaaaat gttcctatgg 7740
atacatatcc cattcatcat ggtgaccctt cctataggac actaaaggag actcagccat 7800
ggtcctctcc caaaggttct gaaggatacc ttgcagccac ctatccaact gtcggccaga 7860
ccagtccccg agccaggaaa tccatgagcc tggacatggg gcaaccttct caggccaaca 7920
ctaagaagtt gcttggaaca aggaaaagtt ttgatcactt gatatcagac acaaaggctc 7980
ctaaaaggca agaaatggaa tcagggatca caacaccccc caaaatgagg agagtagcag 8040
aaactgatta tgaaatggaa actcagagga tttcctcatc acaacagcac ccacatttac 8100
gtaaagtttc agtgtctgaa tcaaatgttc tcttggatga agaagtactt actgatccga 8160
agatccaggc gctgcttctt actgttctag ctacactggt aaaatatacc acagatgagt 8220
ttgatcaacg aattctttat gaatacttag cagaggccag tgttgtgttt cccaaagtct 8280
ttcctgttgt gcataatttg ttggactcta agatcaacac cctgttatca ttgtgccaag 8340
atccaaattt gttaaatcca atccatggaa ttgtgcagag tgtggtgtac catgaagaat 8400
ccccaccaca ataccaaaca tcttacctgc aaagttttgg ttttaatggc ttgtggcggt 8460
ttgcaggacc gttttcaaag caaacacaaa ttccagacta tgctgagctt attgttaagt 8520
ttcttgatgc cttgattgac acgtacctgc ctggaattga tgaagaaacc agtgaagaat 8580
ccctcctgac tcccacatct ccttaccctc ctgcactgca gagccagctt agtatcactg 8640
ccaaccttaa cctttctaat tccatgacct cacttgcaac ttcccagcat tccccaggaa 8700
tcgacaagga gaacgttgaa ctctccccta ccactggcca ctgtaacagt ggacgaactc 8760
gccacggatc cgcaagccaa gtgcagaagc aaagaagcgc tggcagtttc aaacgtaata 8820
gcattaagaa gatcgtgtga agcttgcttg ctttcttttt taaaatcaac ttaacatggg 8880
ctcttcacta gtgacccctt ccctgtcctt gccctttccc cccatgttgt aatgctgcac 8940
ttcctgtttt ataatgaacc catccggttt gccatgttgc cagatgatca actcttcgaa 9000
gccttgccta aatttaatgc tgccttttct ttaacttttt ttcttctact tttggcgtgt 9060
atctggtata tgtaagtgtt cagaacaact gcaaagaaag tgggaggtca ggaaactttt 9120
aactgagaaa tctcaattgt aagagaggat gaattcttga atactgctac tactggccag 9180
tgatgaaagc catttgcaca gagctctgcc ttctgtggtt ttcccttctt catcctacag 9240
agtaaagtgt tagtcctatt tatacatttt tcaagataca agtttatgag agaaatagta 9300
ttataacccc agtatgttta atcttttagc tgtggacttt ttttttaacc gtacaaaact 9360
gaaagaacca tagaggtcaa gcctcagtga cttgacacca taaagccaca gacaaggtac 9420
ttggggggga gggcagggaa atttcatatt ttatagtgga ttcttaagaa atactaacac 9480
ttgagtatta gcaataatta caggaaaata agtgcgacca catatatctt aacattactg 9540
aattaaaact atggcttcta agtccttatc caaactcagt catccaaact agtttatttt 9600
tttctccagt tgattatctt ttaattttta attttgctaa aggtggtttt tttgtgtttt 9660
gttttttgta aaccaaaact atactaagta tagtaattat atatatatat atattttttc 9720
ccctccccct cttctttcct aactaattct gagcagggta atcagtgaac aaagtgttga 9780
aaattgttcc cagaaggtaa ttttcataga tgtttgcatt agctccatag caaaatggaa 9840
tggtacgtga catttagggt agctgatatt tttattttgt taaataattt ccaagaatag 9900
agtatggtgt atattataaa tttctttgat aagatgtatt ttgaatgtct tttaatcttc 9960
ctcctcctct ccaaaaaaat cagaaacctc tttaagaaaa catgtaggtt atatatgcta 10020
gaattgcatt taatcactgt gaaaagactg gtcagcctgc attagtatga cagtaggggg 10080
gctgttagaa ttgctgctat actggtggta tggattatca tggcattgga attttcatag 10140
taatgcagat ccaatttctt tgtggtacct gcagtttaca aaataatttg acttcagtga 10200
gcatattggt atctggatgt tccaatttag aactaaacca tatttattac aaaaagatat 10260
taatccctct actcccaggt tccctttata tgttaagata taatggcttt gaggggggaa 10320
aaaataaacc taggggagag gggagtttcc tgtagtgctg tttcattaga ggatttcagt 10380
aaattaaatt ccacagctaa ttcaataaat aatggtacat ttaagtgttc tgattttaat 10440
aatatatttc acatttatcc acacagtaac aatgtaatat gttaatgtaa ataaaattgg 10500
ttttgatact cagaaataac aagaatttaa ttttttaaat ttgtttacag tcctgggaaa 10560
agtaagaatt atttgccaaa ataagaggaa agaaaacctt agtattatta atgagtttac 10620
catagaattg ttggaaatac tgaagacagg tgcaatttac taaacttttg tttttaaact 10680
attgtagagg ctgcattaga agaaaatgtt tataatgaca gagcaactat gactatataa 10740
aaaagctgaa attagaactg tgtttagaaa tagatcagta acccagtgcc aaggatgcca 10800
agctgccacc atggtcttgg ctctcccaca acccagtgtt tctggggtaa gtttcacagt 10860
ttctaggccc tggaatagca ggcagtgtaa gcctttgata actttagttc gatgtttttc 10920
ttgtttttgt ttgttggttt ggtgcatatg atagtgggtg ttatgctatt ttgctcttcc 10980
catcaaaata aagaaacttc cagaggttta ctgttaaaaa tactgatatt tccataaacg 11040
ggtttaccaa gggtgtagta tttcataccg cctgaaatga tcagcattgg cacaaatcaa 11100
aattcagccg cctttgaaat gcaaaaatac ctttgactag taagtacatc ctaggagttt 11160
gaaaacttaa ctaaggttta aaatttacct tgtttaaaga acttctgact tttgaggaaa 11220
atctagcttt ccaagtaact aaaatgtaca tgagataaac ctctcaccac tatgtgtccc 11280
ttgagaaatg caacactttt ttagtcttca tacttgtaat ctataaaaga aattctgaag 11340
tttagaccaa gttgcccatt tctgcgtaat tgacataagt tctgttaaaa atattataag 11400
taattcgttt cggtttgtag atgtttcccc tgacttgtta aagaggaaac caggaactca 11460
gtcatgtttt tgtcctggat aatctacctg ttatgccagt actcccatcc gaggggcatg 11520
cccttagttg cccagatgga gatgcagttc agtagatttg gggcaaagtg gctacagctc 11580
tgtcttccat tcactcaaca cctgttcatg actgagccag gtgcccagga cacatcctaa 11640
acagtcagct tctatcctgt gtcctagttg gggagacaga gtgccagcca gcaaccctcc 11700
caggtttgta ggttttaggg gttttcagtt ttgtttgggt tttttgtttt ttgtttttgt 11760
ttctacatcc ttccccgact cccaggcata atgaggcatg tcttactcaa tgttatgcaa 11820
tggatttagg caaaaattca ttcttagtgt cagccacaca atttttttta atgcagtata 11880
ttcacctgta aatagtttgt gtaaaatttg acaaaaaaag tatatttact atactgtaaa 11940
tatatgtgat gatatattgt attattttgc ttttttgtaa agcagttagt tgctgcacat 12000
ggataacaac aaaaatttga ttattctcgt gttagtattg ttaacttctt tttgcgactg 12060
cgttacatca tttaaagaaa atgctgtgta ttgtaaactt aaattgtata tgataactta 12120
ctgtcctttc catccgggcc taaactttgg cagttccttt gtctacaacc ttgttaatac 12180
tgtaaacagt tgtacgccag caggaaaaat actgcccaac agacaaaatc gatcattgta 12240
ggggaaaatc atagaaatcc atttcagatc tttattgttc ctcaccccat tttcctcctt 12300
gtgtatgtac ttcccccacc cccctttttt taagtaaaat gtaaattcaa tctgctctaa 12360
gaaaaaaaaa aaaaaaaaaa a 12381
<210> 2
<211> 2839
<212> PRT
<213> Homo sapiens
<400> 2
Met Ala Ala His Arg Pro Val Glu Trp Val Gln Ala Val Val Ser Arg
1 5 10 15
Phe Asp Glu Gln Leu Pro Ile Lys Thr Gly Gln Gln Asn Thr His Thr
20 25 30
Lys Val Ser Thr Glu His Asn Lys Glu Cys Leu Ile Asn Ile Ser Lys
35 40 45
Tyr Lys Phe Ser Leu Val Ile Ser Gly Leu Thr Thr Ile Leu Lys Asn
50 55 60
Val Asn Asn Met Arg Ile Phe Gly Glu Ala Ala Glu Lys Asn Leu Tyr
65 70 75 80
Leu Ser Gln Leu Ile Ile Leu Asp Thr Leu Glu Lys Cys Leu Ala Gly
85 90 95
Gln Pro Lys Asp Thr Met Arg Leu Asp Glu Thr Met Leu Val Lys Gln
100 105 110
Leu Leu Pro Glu Ile Cys His Phe Leu His Thr Cys Arg Glu Gly Asn
115 120 125
Gln His Ala Ala Glu Leu Arg Asn Ser Ala Ser Gly Val Leu Phe Ser
130 135 140
Leu Ser Cys Asn Asn Phe Asn Ala Val Phe Ser Arg Ile Ser Thr Arg
145 150 155 160
Leu Gln Glu Leu Thr Val Cys Ser Glu Asp Asn Val Asp Val His Asp
165 170 175
Ile Glu Leu Leu Gln Tyr Ile Asn Val Asp Cys Ala Lys Leu Lys Arg
180 185 190
Leu Leu Lys Glu Thr Ala Phe Lys Phe Lys Ala Leu Lys Lys Val Ala
195 200 205
Gln Leu Ala Val Ile Asn Ser Leu Glu Lys Ala Phe Trp Asn Trp Val
210 215 220
Glu Asn Tyr Pro Asp Glu Phe Thr Lys Leu Tyr Gln Ile Pro Gln Thr
225 230 235 240
Asp Met Ala Glu Cys Ala Glu Lys Leu Phe Asp Leu Val Asp Gly Phe
245 250 255
Ala Glu Ser Thr Lys Arg Lys Ala Ala Val Trp Pro Leu Gln Ile Ile
260 265 270
Leu Leu Ile Leu Cys Pro Glu Ile Ile Gln Asp Ile Ser Lys Asp Val
275 280 285
Val Asp Glu Asn Asn Met Asn Lys Lys Leu Phe Leu Asp Ser Leu Arg
290 295 300
Lys Ala Leu Ala Gly His Gly Gly Ser Arg Gln Leu Thr Glu Ser Ala
305 310 315 320
Ala Ile Ala Cys Val Lys Leu Cys Lys Ala Ser Thr Tyr Ile Asn Trp
325 330 335
Glu Asp Asn Ser Val Ile Phe Leu Leu Val Gln Ser Met Val Val Asp
340 345 350
Leu Lys Asn Leu Leu Phe Asn Pro Ser Lys Pro Phe Ser Arg Gly Ser
355 360 365
Gln Pro Ala Asp Val Asp Leu Met Ile Asp Cys Leu Val Ser Cys Phe
370 375 380
Arg Ile Ser Pro His Asn Asn Gln His Phe Lys Ile Cys Leu Ala Gln
385 390 395 400
Asn Ser Pro Ser Thr Phe His Tyr Val Leu Val Asn Ser Leu His Arg
405 410 415
Ile Ile Thr Asn Ser Ala Leu Asp Trp Trp Pro Lys Ile Asp Ala Val
420 425 430
Tyr Cys His Ser Val Glu Leu Arg Asn Met Phe Gly Glu Thr Leu His
435 440 445
Lys Ala Val Gln Gly Cys Gly Ala His Pro Ala Ile Arg Met Ala Pro
450 455 460
Ser Leu Thr Phe Lys Glu Lys Val Thr Ser Leu Lys Phe Lys Glu Lys
465 470 475 480
Pro Thr Asp Leu Glu Thr Arg Ser Tyr Lys Tyr Leu Leu Leu Ser Met
485 490 495
Val Lys Leu Ile His Ala Asp Pro Lys Leu Leu Leu Cys Asn Pro Arg
500 505 510
Lys Gln Gly Pro Glu Thr Gln Gly Ser Thr Ala Glu Leu Ile Thr Gly
515 520 525
Leu Val Gln Leu Val Pro Gln Ser His Met Pro Glu Ile Ala Gln Glu
530 535 540
Ala Met Glu Ala Leu Leu Val Leu His Gln Leu Asp Ser Ile Asp Leu
545 550 555 560
Trp Asn Pro Asp Ala Pro Val Glu Thr Phe Trp Glu Ile Ser Ser Gln
565 570 575
Met Leu Phe Tyr Ile Cys Lys Lys Leu Thr Ser His Gln Met Leu Ser
580 585 590
Ser Thr Glu Ile Leu Lys Trp Leu Arg Glu Ile Leu Ile Cys Arg Asn
595 600 605
Lys Phe Leu Leu Lys Asn Lys Gln Ala Asp Arg Ser Ser Cys His Phe
610 615 620
Leu Leu Phe Tyr Gly Val Gly Cys Asp Ile Pro Ser Ser Gly Asn Thr
625 630 635 640
Ser Gln Met Ser Met Asp His Glu Glu Leu Leu Arg Thr Pro Gly Ala
645 650 655
Ser Leu Arg Lys Gly Lys Gly Asn Ser Ser Met Asp Ser Ala Ala Gly
660 665 670
Cys Ser Gly Thr Pro Pro Ile Cys Arg Gln Ala Gln Thr Lys Leu Glu
675 680 685
Val Ala Leu Tyr Met Phe Leu Trp Asn Pro Asp Thr Glu Ala Val Leu
690 695 700
Val Ala Met Ser Cys Phe Arg His Leu Cys Glu Glu Ala Asp Ile Arg
705 710 715 720
Cys Gly Val Asp Glu Val Ser Val His Asn Leu Leu Pro Asn Tyr Asn
725 730 735
Thr Phe Met Glu Phe Ala Ser Val Ser Asn Met Met Ser Thr Gly Arg
740 745 750
Ala Ala Leu Gln Lys Arg Val Met Ala Leu Leu Arg Arg Ile Glu His
755 760 765
Pro Thr Ala Gly Asn Thr Glu Ala Trp Glu Asp Thr His Ala Lys Trp
770 775 780
Glu Gln Ala Thr Lys Leu Ile Leu Asn Tyr Pro Lys Ala Lys Met Glu
785 790 795 800
Asp Gly Gln Ala Ala Glu Ser Leu His Lys Thr Ile Val Lys Arg Arg
805 810 815
Met Ser His Val Ser Gly Gly Gly Ser Ile Asp Leu Ser Asp Thr Asp
820 825 830
Ser Leu Gln Glu Trp Ile Asn Met Thr Gly Phe Leu Cys Ala Leu Gly
835 840 845
Gly Val Cys Leu Gln Gln Arg Ser Asn Ser Gly Leu Ala Thr Tyr Ser
850 855 860
Pro Pro Met Gly Pro Val Ser Glu Arg Lys Gly Ser Met Ile Ser Val
865 870 875 880
Met Ser Ser Glu Gly Asn Ala Asp Thr Pro Val Ser Lys Phe Met Asp
885 890 895
Arg Leu Leu Ser Leu Met Val Cys Asn His Glu Lys Val Gly Leu Gln
900 905 910
Ile Arg Thr Asn Val Lys Asp Leu Val Gly Leu Glu Leu Ser Pro Ala
915 920 925
Leu Tyr Pro Met Leu Phe Asn Lys Leu Lys Asn Thr Ile Ser Lys Phe
930 935 940
Phe Asp Ser Gln Gly Gln Val Leu Leu Thr Asp Thr Asn Thr Gln Phe
945 950 955 960
Val Glu Gln Thr Ile Ala Ile Met Lys Asn Leu Leu Asp Asn His Thr
965 970 975
Glu Gly Ser Ser Glu His Leu Gly Gln Ala Ser Ile Glu Thr Met Met
980 985 990
Leu Asn Leu Val Arg Tyr Val Arg Val Leu Gly Asn Met Val His Ala
995 1000 1005
Ile Gln Ile Lys Thr Lys Leu Cys Gln Leu Val Glu Val Met Met Ala
1010 1015 1020
Arg Arg Asp Asp Leu Ser Phe Cys Gln Glu Met Lys Phe Arg Asn Lys
1025 1030 1035 1040
Met Val Glu Tyr Leu Thr Asp Trp Val Met Gly Thr Ser Asn Gln Ala
1045 1050 1055
Ala Asp Asp Asp Val Lys Cys Leu Thr Arg Asp Leu Asp Gln Ala Ser
1060 1065 1070
Met Glu Ala Val Val Ser Leu Leu Ala Gly Leu Pro Leu Gln Pro Glu
1075 1080 1085
Glu Gly Asp Gly Val Glu Leu Met Glu Ala Lys Ser Gln Leu Phe Leu
1090 1095 1100
Lys Tyr Phe Thr Leu Phe Met Asn Leu Leu Asn Asp Cys Ser Glu Val
1105 1110 1115 1120
Glu Asp Glu Ser Ala Gln Thr Gly Gly Arg Lys Arg Gly Met Ser Arg
1125 1130 1135
Arg Leu Ala Ser Leu Arg His Cys Thr Val Leu Ala Met Ser Asn Leu
1140 1145 1150
Leu Asn Ala Asn Val Asp Ser Gly Leu Met His Ser Ile Gly Leu Gly
1155 1160 1165
Tyr His Lys Asp Leu Gln Thr Arg Ala Thr Phe Met Glu Val Leu Thr
1170 1175 1180
Lys Ile Leu Gln Gln Gly Thr Glu Phe Asp Thr Leu Ala Glu Thr Val
1185 1190 1195 1200
Leu Ala Asp Arg Phe Glu Arg Leu Val Glu Leu Val Thr Met Met Gly
1205 1210 1215
Asp Gln Gly Glu Leu Pro Ile Ala Met Ala Leu Ala Asn Val Val Pro
1220 1225 1230
Cys Ser Gln Trp Asp Glu Leu Ala Arg Val Leu Val Thr Leu Phe Asp
1235 1240 1245
Ser Arg His Leu Leu Tyr Gln Leu Leu Trp Asn Met Phe Ser Lys Glu
1250 1255 1260
Val Glu Leu Ala Asp Ser Met Gln Thr Leu Phe Arg Gly Asn Ser Leu
1265 1270 1275 1280
Ala Ser Lys Ile Met Thr Phe Cys Phe Lys Val Tyr Gly Ala Thr Tyr
1285 1290 1295
Leu Gln Lys Leu Leu Asp Pro Leu Leu Arg Ile Val Ile Thr Ser Ser
1300 1305 1310
Asp Trp Gln His Val Ser Phe Glu Val Asp Pro Thr Arg Leu Glu Pro
1315 1320 1325
Ser Glu Ser Leu Glu Glu Asn Gln Arg Asn Leu Leu Gln Met Thr Glu
1330 1335 1340
Lys Phe Phe His Ala Ile Ile Ser Ser Ser Ser Glu Phe Pro Pro Gln
1345 1350 1355 1360
Leu Arg Ser Val Cys His Cys Leu Tyr Gln Ala Thr Cys His Ser Leu
1365 1370 1375
Leu Asn Lys Ala Thr Val Lys Glu Lys Lys Glu Asn Lys Lys Ser Val
1380 1385 1390
Val Ser Gln Arg Phe Pro Gln Asn Ser Ile Gly Ala Val Gly Ser Ala
1395 1400 1405
Met Phe Leu Arg Phe Ile Asn Pro Ala Ile Val Ser Pro Tyr Glu Ala
1410 1415 1420
Gly Ile Leu Asp Lys Lys Pro Pro Pro Arg Ile Glu Arg Gly Leu Lys
1425 1430 1435 1440
Leu Met Ser Lys Ile Leu Gln Ser Ile Ala Asn His Val Leu Phe Thr
1445 1450 1455
Lys Glu Glu His Met Arg Pro Phe Asn Asp Phe Val Lys Ser Asn Phe
1460 1465 1470
Asp Ala Ala Arg Arg Phe Phe Leu Asp Ile Ala Ser Asp Cys Pro Thr
1475 1480 1485
Ser Asp Ala Val Asn His Ser Leu Ser Phe Ile Ser Asp Gly Asn Val
1490 1495 1500
Leu Ala Leu His Arg Leu Leu Trp Asn Asn Gln Glu Lys Ile Gly Gln
1505 1510 1515 1520
Tyr Leu Ser Ser Asn Arg Asp His Lys Ala Val Gly Arg Arg Pro Phe
1525 1530 1535
Asp Lys Met Ala Thr Leu Leu Ala Tyr Leu Gly Pro Pro Glu His Lys
1540 1545 1550
Pro Val Ala Asp Thr His Trp Ser Ser Leu Asn Leu Thr Ser Ser Lys
1555 1560 1565
Phe Glu Glu Phe Met Thr Arg His Gln Val His Glu Lys Glu Glu Phe
1570 1575 1580
Lys Ala Leu Lys Thr Leu Ser Ile Phe Tyr Gln Ala Gly Thr Ser Lys
1585 1590 1595 1600
Ala Gly Asn Pro Ile Phe Tyr Tyr Val Ala Arg Arg Phe Lys Thr Gly
1605 1610 1615
Gln Ile Asn Gly Asp Leu Leu Ile Tyr His Val Leu Leu Thr Leu Lys
1620 1625 1630
Pro Tyr Tyr Ala Lys Pro Tyr Glu Ile Val Val Asp Leu Thr His Thr
1635 1640 1645
Gly Pro Ser Asn Arg Phe Lys Thr Asp Phe Leu Ser Lys Trp Phe Val
1650 1655 1660
Val Phe Pro Gly Phe Ala Tyr Asp Asn Val Ser Ala Val Tyr Ile Tyr
1665 1670 1675 1680
Asn Cys Asn Ser Trp Val Arg Glu Tyr Thr Lys Tyr His Glu Arg Leu
1685 1690 1695
Leu Thr Gly Leu Lys Gly Ser Lys Arg Leu Val Phe Ile Asp Cys Pro
1700 1705 1710
Gly Lys Leu Ala Glu His Ile Glu His Glu Gln Gln Lys Leu Pro Ala
1715 1720 1725
Ala Thr Leu Ala Leu Glu Glu Asp Leu Lys Val Phe His Asn Ala Leu
1730 1735 1740
Lys Leu Ala His Lys Asp Thr Lys Val Ser Ile Lys Val Gly Ser Thr
1745 1750 1755 1760
Ala Val Gln Val Thr Ser Ala Glu Arg Thr Lys Val Leu Gly Gln Ser
1765 1770 1775
Val Phe Leu Asn Asp Ile Tyr Tyr Ala Ser Glu Ile Glu Glu Ile Cys
1780 1785 1790
Leu Val Asp Glu Asn Gln Phe Thr Leu Thr Ile Ala Asn Gln Gly Thr
1795 1800 1805
Pro Leu Thr Phe Met His Gln Glu Cys Glu Ala Ile Val Gln Ser Ile
1810 1815 1820
Ile His Ile Arg Thr Arg Trp Glu Leu Ser Gln Pro Asp Ser Ile Pro
1825 1830 1835 1840
Gln His Thr Lys Ile Arg Pro Lys Asp Val Pro Gly Thr Leu Leu Asn
1845 1850 1855
Ile Ala Leu Leu Asn Leu Gly Ser Ser Asp Pro Ser Leu Arg Ser Ala
1860 1865 1870
Ala Tyr Asn Leu Leu Cys Ala Leu Thr Cys Thr Phe Asn Leu Lys Ile
1875 1880 1885
Glu Gly Gln Leu Leu Glu Thr Ser Gly Leu Cys Ile Pro Ala Asn Asn
1890 1895 1900
Thr Leu Phe Ile Val Ser Ile Ser Lys Thr Leu Ala Ala Asn Glu Pro
1905 1910 1915 1920
His Leu Thr Leu Glu Phe Leu Glu Glu Cys Ile Ser Gly Phe Ser Lys
1925 1930 1935
Ser Ser Ile Glu Leu Lys His Leu Cys Leu Glu Tyr Met Thr Pro Trp
1940 1945 1950
Leu Ser Asn Leu Val Arg Phe Cys Lys His Asn Asp Asp Ala Lys Arg
1955 1960 1965
Gln Arg Val Thr Ala Ile Leu Asp Lys Leu Ile Thr Met Thr Ile Asn
1970 1975 1980
Glu Lys Gln Met Tyr Pro Ser Ile Gln Ala Lys Ile Trp Gly Ser Leu
1985 1990 1995 2000
Gly Gln Ile Thr Asp Leu Leu Asp Val Val Leu Asp Ser Phe Ile Lys
2005 2010 2015
Thr Ser Ala Thr Gly Gly Leu Gly Ser Ile Lys Ala Glu Val Met Ala
2020 2025 2030
Asp Thr Ala Val Ala Leu Ala Ser Gly Asn Val Lys Leu Val Ser Ser
2035 2040 2045
Lys Val Ile Gly Arg Met Cys Lys Ile Ile Asp Lys Thr Cys Leu Ser
2050 2055 2060
Pro Thr Pro Thr Leu Glu Gln His Leu Met Trp Asp Asp Ile Ala Ile
2065 2070 2075 2080
Leu Ala Arg Tyr Met Leu Met Leu Ser Phe Asn Asn Ser Leu Asp Val
2085 2090 2095
Ala Ala His Leu Pro Tyr Leu Phe His Val Val Thr Phe Leu Val Ala
2100 2105 2110
Thr Gly Pro Leu Ser Leu Arg Ala Ser Thr His Gly Leu Val Ile Asn
2115 2120 2125
Ile Ile His Ser Leu Cys Thr Cys Ser Gln Leu His Phe Ser Glu Glu
2130 2135 2140
Thr Lys Gln Val Leu Arg Leu Ser Leu Thr Glu Phe Ser Leu Pro Lys
2145 2150 2155 2160
Phe Tyr Leu Leu Phe Gly Ile Ser Lys Val Lys Ser Ala Ala Val Ile
2165 2170 2175
Ala Phe Arg Ser Ser Tyr Arg Asp Arg Ser Phe Ser Pro Gly Ser Tyr
2180 2185 2190
Glu Arg Glu Thr Phe Ala Leu Thr Ser Leu Glu Thr Val Thr Glu Ala
2195 2200 2205
Leu Leu Glu Ile Met Glu Ala Cys Met Arg Asp Ile Pro Thr Cys Lys
2210 2215 2220
Trp Leu Asp Gln Trp Thr Glu Leu Ala Gln Arg Phe Ala Phe Gln Tyr
2225 2230 2235 2240
Asn Pro Ser Leu Gln Pro Arg Ala Leu Val Val Phe Gly Cys Ile Ser
2245 2250 2255
Lys Arg Val Ser His Gly Gln Ile Lys Gln Ile Ile Arg Ile Leu Ser
2260 2265 2270
Lys Ala Leu Glu Ser Cys Leu Lys Gly Pro Asp Thr Tyr Asn Ser Gln
2275 2280 2285
Val Leu Ile Glu Ala Thr Val Ile Ala Leu Thr Lys Leu Gln Pro Leu
2290 2295 2300
Leu Asn Lys Asp Ser Pro Leu His Lys Ala Leu Phe Trp Val Ala Val
2305 2310 2315 2320
Ala Val Leu Gln Leu Asp Glu Val Asn Leu Tyr Ser Ala Gly Thr Ala
2325 2330 2335
Leu Leu Glu Gln Asn Leu His Thr Leu Asp Ser Leu Arg Ile Phe Asn
2340 2345 2350
Asp Lys Ser Pro Glu Glu Val Phe Met Ala Ile Arg Asn Pro Leu Glu
2355 2360 2365
Trp His Cys Lys Gln Met Asp His Phe Val Gly Leu Asn Phe Asn Ser
2370 2375 2380
Asn Phe Asn Phe Ala Leu Val Gly His Leu Leu Lys Gly Tyr Arg His
2385 2390 2395 2400
Pro Ser Pro Ala Ile Val Ala Arg Thr Val Arg Ile Leu His Thr Leu
2405 2410 2415
Leu Thr Leu Val Asn Lys His Arg Asn Cys Asp Lys Phe Glu Val Asn
2420 2425 2430
Thr Gln Ser Val Ala Tyr Leu Ala Ala Leu Leu Thr Val Ser Glu Glu
2435 2440 2445
Val Arg Ser Arg Cys Ser Leu Lys His Arg Lys Ser Leu Leu Leu Thr
2450 2455 2460
Asp Ile Ser Met Glu Asn Val Pro Met Asp Thr Tyr Pro Ile His His
2465 2470 2475 2480
Gly Asp Pro Ser Tyr Arg Thr Leu Lys Glu Thr Gln Pro Trp Ser Ser
2485 2490 2495
Pro Lys Gly Ser Glu Gly Tyr Leu Ala Ala Thr Tyr Pro Thr Val Gly
2500 2505 2510
Gln Thr Ser Pro Arg Ala Arg Lys Ser Met Ser Leu Asp Met Gly Gln
2515 2520 2525
Pro Ser Gln Ala Asn Thr Lys Lys Leu Leu Gly Thr Arg Lys Ser Phe
2530 2535 2540
Asp His Leu Ile Ser Asp Thr Lys Ala Pro Lys Arg Gln Glu Met Glu
2545 2550 2555 2560
Ser Gly Ile Thr Thr Pro Pro Lys Met Arg Arg Val Ala Glu Thr Asp
2565 2570 2575
Tyr Glu Met Glu Thr Gln Arg Ile Ser Ser Ser Gln Gln His Pro His
2580 2585 2590
Leu Arg Lys Val Ser Val Ser Glu Ser Asn Val Leu Leu Asp Glu Glu
2595 2600 2605
Val Leu Thr Asp Pro Lys Ile Gln Ala Leu Leu Leu Thr Val Leu Ala
2610 2615 2620
Thr Leu Val Lys Tyr Thr Thr Asp Glu Phe Asp Gln Arg Ile Leu Tyr
2625 2630 2635 2640
Glu Tyr Leu Ala Glu Ala Ser Val Val Phe Pro Lys Val Phe Pro Val
2645 2650 2655
Val His Asn Leu Leu Asp Ser Lys Ile Asn Thr Leu Leu Ser Leu Cys
2660 2665 2670
Gln Asp Pro Asn Leu Leu Asn Pro Ile His Gly Ile Val Gln Ser Val
2675 2680 2685
Val Tyr His Glu Glu Ser Pro Pro Gln Tyr Gln Thr Ser Tyr Leu Gln
2690 2695 2700
Ser Phe Gly Phe Asn Gly Leu Trp Arg Phe Ala Gly Pro Phe Ser Lys
2705 2710 2715 2720
Gln Thr Gln Ile Pro Asp Tyr Ala Glu Leu Ile Val Lys Phe Leu Asp
2725 2730 2735
Ala Leu Ile Asp Thr Tyr Leu Pro Gly Ile Asp Glu Glu Thr Ser Glu
2740 2745 2750
Glu Ser Leu Leu Thr Pro Thr Ser Pro Tyr Pro Pro Ala Leu Gln Ser
2755 2760 2765
Gln Leu Ser Ile Thr Ala Asn Leu Asn Leu Ser Asn Ser Met Thr Ser
2770 2775 2780
Leu Ala Thr Ser Gln His Ser Pro Gly Ile Asp Lys Glu Asn Val Glu
2785 2790 2795 2800
Leu Ser Pro Thr Thr Gly His Cys Asn Ser Gly Arg Thr Arg His Gly
2805 2810 2815
Ser Ala Ser Gln Val Gln Lys Gln Arg Ser Ala Gly Ser Phe Lys Arg
2820 2825 2830
Asn Ser Ile Lys Lys Ile Val
2835

Claims (10)

1.一种NF1新突变致病基因,其特征在于,所述新突变致病基因的核酸样本与NF1基因如SEQ ID NO:1所示的核苷酸序列相比,核苷酸变化:c.738delA。
2.权利要求1所述的NF1新突变致病基因,其特征在于,所述突变致病基因的核酸样本指人工分离或合成的单链DNA、双链DNA、RNA或DNA与RNA的聚合物。
3.一种视网膜变性疾病的NF1新突变体蛋白质,其特征在于,所述蛋白质的氨基酸序列与SEQ ID NO:2所示的氨基酸序列相比,氨基酸变化:p.E247KfsTer34。
4.根据权利3所述的蛋白质,其特征在于,所述蛋白质由权利要求1所述的基因编码的。
5.权利要求1或2所述的新突变致病基因在制备检测或筛选NF1病变的试剂盒中的应用。
6.筛选NF1病变的试剂盒的试剂盒,其特征在于,所述试剂盒包含检测权利要求1所述的NF1新突变致病基因的试剂,所述新突变致病基因与NF1基因如SEQ ID NO:1所示的核苷酸序列相比,具有核苷酸变化:c.738delA。
7.根据权利要求6所述的试剂盒,其特征在于,所述检测NF1新突变致病基因的试剂是核酸探针。
8.根据权利要求6所述的试剂盒,其特征在于,所述试剂盒包括序列如SEQ ID NO:15和/或SEQ ID NO:16的引物。
9.根据权利要求6所述的试剂盒,其特征在于,所述检测NF1新突变致病基因的试剂是检测致病基因所编码的蛋白。
10.根据权利要求9所述的试剂盒,其特征在于,所述蛋白的氨基酸与SEQ ID NO:2所示的氨基酸序列相比,具有p.E247KfsTer34突变。
CN201910530764.4A 2019-06-19 2019-06-19 一种nf1新突变致病基因及应用和试剂盒 Expired - Fee Related CN110184275B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910530764.4A CN110184275B (zh) 2019-06-19 2019-06-19 一种nf1新突变致病基因及应用和试剂盒

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910530764.4A CN110184275B (zh) 2019-06-19 2019-06-19 一种nf1新突变致病基因及应用和试剂盒

Publications (2)

Publication Number Publication Date
CN110184275A true CN110184275A (zh) 2019-08-30
CN110184275B CN110184275B (zh) 2021-06-04

Family

ID=67722393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910530764.4A Expired - Fee Related CN110184275B (zh) 2019-06-19 2019-06-19 一种nf1新突变致病基因及应用和试剂盒

Country Status (1)

Country Link
CN (1) CN110184275B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116083560A (zh) * 2023-01-18 2023-05-09 北京大学第三医院(北京大学第三临床医学院) 一种用于着床前胚胎nf1基因检测的试剂盒、系统及其应用方法
CN117431323A (zh) * 2023-12-20 2024-01-23 广州嘉检医学检测有限公司 一种nf1基因检测试剂及检测方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029251A2 (en) * 1999-10-18 2001-04-26 Universiteit Gent Improved mutation analysis of the nf1 gene
CN103045605A (zh) * 2012-12-26 2013-04-17 首都医科大学宣武医院 一种与脑血管狭窄有关的ⅰ型神经纤维瘤nf1基因突变核苷酸序列及其应用
US20140113960A1 (en) * 2012-04-02 2014-04-24 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US20140309292A1 (en) * 2011-11-21 2014-10-16 The Royal Institution For The Advancement Of Learning/Mcgill University Mutations of Histone Proteins Associated with Proliferative Disorders
CN104745697A (zh) * 2015-03-24 2015-07-01 济南艾迪康医学检验中心有限公司 检测nf1基因第31-34号全外显子的方法和引物
CN104878079A (zh) * 2014-06-26 2015-09-02 首都医科大学附属北京天坛医院 一种用于体外检测Neurofibromastosis2疾病致病基因NF2的c.1598delA突变的试剂盒
CN106755399A (zh) * 2016-12-21 2017-05-31 杭州艾诺医学检验所有限公司 一种i型神经纤维瘤病致病基因突变及基于此基因突变的病因学诊断试剂
KR101925974B1 (ko) * 2017-04-05 2018-12-06 울산대학교 산학협력단 게놈 dna 기반의 장 pcr 프라이머 세트를 포함하는 신경섬유종증 진단용 조성물
CN109880910A (zh) * 2019-04-25 2019-06-14 南京世和基因生物技术有限公司 一种肿瘤突变负荷的检测位点组合、检测方法、检测试剂盒及系统

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029251A2 (en) * 1999-10-18 2001-04-26 Universiteit Gent Improved mutation analysis of the nf1 gene
US20140309292A1 (en) * 2011-11-21 2014-10-16 The Royal Institution For The Advancement Of Learning/Mcgill University Mutations of Histone Proteins Associated with Proliferative Disorders
US20140113960A1 (en) * 2012-04-02 2014-04-24 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
CN103045605A (zh) * 2012-12-26 2013-04-17 首都医科大学宣武医院 一种与脑血管狭窄有关的ⅰ型神经纤维瘤nf1基因突变核苷酸序列及其应用
CN104878079A (zh) * 2014-06-26 2015-09-02 首都医科大学附属北京天坛医院 一种用于体外检测Neurofibromastosis2疾病致病基因NF2的c.1598delA突变的试剂盒
CN104745697A (zh) * 2015-03-24 2015-07-01 济南艾迪康医学检验中心有限公司 检测nf1基因第31-34号全外显子的方法和引物
CN106755399A (zh) * 2016-12-21 2017-05-31 杭州艾诺医学检验所有限公司 一种i型神经纤维瘤病致病基因突变及基于此基因突变的病因学诊断试剂
KR101925974B1 (ko) * 2017-04-05 2018-12-06 울산대학교 산학협력단 게놈 dna 기반의 장 pcr 프라이머 세트를 포함하는 신경섬유종증 진단용 조성물
CN109880910A (zh) * 2019-04-25 2019-06-14 南京世和基因生物技术有限公司 一种肿瘤突变负荷的检测位点组合、检测方法、检测试剂盒及系统

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
KHAOULA ROCHDI等: "First Characterization of Congenital Myasthenic Syndrome Type 5 in North Africa", 《RESEARCH SQUARE》 *
MARGRAF RL等: "Homo sapiens neurofibromin 1 (NF1), transcript variant 2, mRNA", 《GENBANK DATABASE》 *
MARGRAF RL等: "neurofibromin isoform 1 [Homo sapiens]", 《GENBANK DATABASE》 *
MUKHOPADHYAY D等: "Homo sapiens neurofibromin 1 (NF1), RefSeqGene (LRG_214) on chromosome 17", 《GENBANK DATABASE》 *
NEIRA JL等: "Homo sapiens neurofibromin 1 (NF1), transcript variant 1, mRNA", 《GENBANK DATABASE》 *
ROBERT J NICHOLS等: "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers", 《NATURE CELL BIOLOGY》 *
姚林林: "NF1微基因及突变体微基因的克隆与鉴定", 《基因组学与应用生物学》 *
朱铁山等: "一例神经纤维瘤病I型患者NFl基因新的插入缺失型突变", 《中国医学遗传学杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116083560A (zh) * 2023-01-18 2023-05-09 北京大学第三医院(北京大学第三临床医学院) 一种用于着床前胚胎nf1基因检测的试剂盒、系统及其应用方法
CN116083560B (zh) * 2023-01-18 2024-01-23 北京大学第三医院(北京大学第三临床医学院) 一种用于着床前胚胎nf1基因检测的试剂盒、系统及其应用方法
CN117431323A (zh) * 2023-12-20 2024-01-23 广州嘉检医学检测有限公司 一种nf1基因检测试剂及检测方法
CN117431323B (zh) * 2023-12-20 2024-04-30 广州嘉检医学检测有限公司 一种nf1基因检测试剂及检测方法

Also Published As

Publication number Publication date
CN110184275B (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
Soong et al. Spinocerebellar ataxias
Trivier et al. Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome
Michaelides et al. Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis
Stoilova et al. Novel TIGR/MYOC mutations in families with juvenile onset primary open angle glaucoma.
CN108350463A (zh) 通过靶向光受体治疗失明的新型治疗工具和方法
Zeitz et al. Identification and functional characterization of a novel rhodopsin mutation associated with autosomal dominant CSNB
Auslender et al. A common founder mutation of CERKL underlies autosomal recessive retinal degeneration with early macular involvement among Yemenite Jews
JPH09507752A (ja) 結節硬化症2遺伝子及びその利用
CN110241202A (zh) 视网膜色素变性突变位点及其应用
CN110184275A (zh) 一种nf1新突变致病基因及应用和试剂盒
CN106661581A (zh) 新的samdori2基因及其用途
CN104975104A (zh) 阿尔茨海默病诊治标志物及其应用
CN106282197B (zh) 一种遗传性视网膜色素变性疾病的致病突变及其检测试剂
Ladekjaer-Mikkelsen et al. A new mechanism in blue cone monochromatism
Souied et al. A novel ABCR nonsense mutation responsible for late-onset fundus flavimaculatus
Oki et al. A Japanese family with autosomal dominant oculocutaneous albinism type 4
CN105624167B (zh) 一种遗传性中心性晕轮状视网膜病变的致病突变及其检测试剂
Sodi et al. A novel mutation in the VMD2 gene in an Italian family with Best maculopathy
CN108715838B (zh) 原发性家族性脑钙化症致病基因myorg及其应用
CN108866067B (zh) 一种雷伯氏先天性黑矇的致病突变及其检测试剂
Hiriyanna et al. Searching for genotype-phenotype correlations in X-linked juvenile retinoschisis
CN111004844B (zh) 原发性家族性脑钙化致病基因jam2及其应用
Margolis et al. Huntington's disease-like 2: a clinical, pathological, and molecular comparison to Huntington's disease
JP4776841B2 (ja) 脈管形成分野におけるKrit1遺伝子の使用
JP2003088375A (ja) アプラタキシン遺伝子に基づく脊髄小脳変性症(eaoh)の診断および治療への応用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210604

CF01 Termination of patent right due to non-payment of annual fee